WAYNE, Pa. — August 7, 2025 — Leads & Copy — Avalo Therapeutics, Inc. (Nasdaq: AVTX) reported business updates and financial results for Q2 2025, with topline data from the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa expected mid-2026.
The company’s cash and short-term investments totaled approximately $113 million as of June 30, 2025, projected to fund operations into 2028. Rita Jain, M.D., has been appointed to the Board of Directors.
According to Dr. Garry Neil, Chief Executive Officer, the LOTUS trial has enrolled over three-quarters of planned patients and is on track for completion by year-end, with Phase 3 readiness in view.
Financial highlights for the second quarter include research and development expenses of $14.1 million and general and administrative expenses of $5.2 million. Net loss for the quarter was $20.8 million, compared to a net income of $98.5 million for the same period in 2024. Basic and diluted net loss per share were $1.92.
Avalo Therapeutics is focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. The LOTUS trial is evaluating the efficacy and safety of AVTX-009 in adults with hidradenitis suppurativa.
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
Lauren Glaser
Meru Advisors
lglaser@meruadvisors.com
Source: Avalo Therapeutics, Inc.
